Daiichi Sankyo Just Poached Novartis's Drug Approval Machine

Why Daiichi Needs a New Playbook

Daiichi Sankyo has had a phenomenal run with ADCs, drugs that work like biological smart bombs, attaching a toxic payload to an antibody that targets cancer cells specifically. Their flagship, Enhertu, has become a commercial juggernaut in breast and lung cancer. The company is planning five ADC launches in 2026 alone.

But cracks are forming. In January 2026, Daiichi discontinued DS-9606, a next-generation ADC targeting germ cell tumors, citing portfolio priorities. A key clinical trial for Datroway, another major ADC in their pipeline, being co-developed with AstraZeneca, got pushed to the second half of 2026 after slower-than-expected results.

When your core technology platform starts stumbling, you've got two options: double down or diversify. Daiichi is clearly choosing door number two.

The company has been signaling a push into cardiovascular-metabolic diseases and kidney disease alongside its oncology work. But talk is cheap in pharma. Hiring John Tsai is the equivalent of putting your money where your mouth is — with a very large check.

The Syncona Detour

Tsai didn't come straight from Novartis. He left in April 2022 during a corporate restructuring and landed at Syncona Investment Management, a venture capital firm where he served as Executive Partner. His job? Starting new biotech companies from scratch.

The focus areas are telling: oncology, cardiovascular, and kidney disease, the exact therapeutic areas Daiichi Sankyo wants to expand into. Tsai even became CEO of Forcefield Therapeutics, a startup developing treatments to protect the heart.

This VC detour might actually make Tsai more valuable, not less. He's spent the last few years building companies from the ground up, thinking about which science is worth betting on before a single patient is enrolled. That's a different muscle than running trials at a 100,000-person pharma company. And it's exactly the muscle you need when you're trying to build new therapeutic franchises from scratch.

A Bigger Restructuring Play

Tsai's hire isn't happening in isolation. Daiichi Sankyo announced a broader organizational shakeup effective April 1, creating several new leadership units. Ken Keller takes over Global Oncology Business. Koji Sato heads a new Technology Unit. And Tetsuya Ohira becomes Chief Business Transformation Officer.

The restructuring also eliminated old executive titles like "Executive Vice President" and "Senior Executive Officer." It's the kind of corporate spring cleaning that signals a company resetting for its next act. Daiichi CEO Hiroyuki Okuzawa framed the move around the company's next five-year business plan, saying Tsai would bring "unique expertise to our continued pursuit of cutting-edge science and technology."

Translation: the ADC era built Daiichi Sankyo's reputation. The next era needs to build something broader.

What This Really Means

Let's zoom out. Daiichi Sankyo is essentially trying to pull off one of the hardest moves in pharma: evolving from a one-platform company into a diversified drug development powerhouse while that platform is still generating revenue.

It's like a basketball team that built its dynasty around three-point shooting now trying to develop a dominant inside game. You don't stop shooting threes. But you recognize that eventually, defenses adjust, and you need more ways to score.

Tsai's background makes the strategy legible. At Novartis, he didn't just work in one modality; he worked across gene therapy, cell therapy, radioligands, and targeted small molecules simultaneously. He's managed pipelines with over 45 compounds across more than 70 programs. That breadth is rare, and it's precisely what Daiichi needs as it pushes into cardiovascular and kidney disease while keeping its ADC engine running.

The risk? Diversification is expensive and slow. Plenty of pharma companies have tried to branch out from their core strength and ended up diluting both the old franchise and the new one. Tsai will need to balance protecting Daiichi's ADC dominance (still the crown jewel) while placing smart bets in therapeutic areas where the company has less institutional knowledge.

But if his track record is any guide, the man knows how to run a pipeline. Fifteen approvals at Novartis isn't luck. It's a system. And Daiichi Sankyo just hired the guy who built it.

Roche's New Breast Cancer Pill Has a Secret Weapon

Roche's oral breast cancer drug giredestrant just got its FDA date, and its secret weapon isn't the drug itself. It's the combination strategy that cut disease progression by 62% in the patients who need it most.